Important Safety Information
†Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.
High concentration NO delivery has a demonstrated safety record in people and animals with Beyond Air’s LungFit technology. In addition to being a bronchodilator, NO also has been shown to have anti-inflammatory effects and eliminate some viruses. Beyond Air have embarked on a program to address the needs of patients with severe lung infections using LungFit, starting with acute viral pneumonia (including COVID-19) and Nontuberculous Mycobacteria (NTM)
LungFit for Severe Lung Infections
LungFit PRO in pilot acute viral pneumonia study
LungFit GO in pilot NTM study
Simple, safe and convenient
Easy to Use
Portable
One system can treat multiple patients
One Respiratory Therapist (RT) can operate multiple systems
Resources to Learn More
- Non Tuberculous Mycobacteria (NTM) Overview
- FDA Workshop: Development of Antibacterial Drugs for the Treatment of Nontuberculous Mycobacterial Disease: Event Materials
- FDA Workshop: Development of Antibacterial Drugs for the Treatment of Nontuberculous Mycobacterial Disease: Transcript
- FDA: Development of Antibacterial Drugs for NTM: A Regulatory Perspective
- New data on RSV Burden and Management
- Regulatory Aspects of Drug Development for Nontuberculous Mycobacteria Pulmonary Infections
- Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease
- FDA: Public Meeting on Non-Tuberculous Mycobacterial (NTM) Lung Infections Patient – Focused Drug Development
- Quality of Life – Nontuberculous Mycobacteria (NTM) Module
- The Voice of the Patient
- Why Do I (and so many others) Have NTM Lung Infections?
- AIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference
- Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection